Form Type:  CT ORDER
Filing Date:  11/8/2018 
CIK:  0000921299 
Address:  409 ILLINOIS STREET 
City, State, Zip:  SAN FRANCISCO, California 94158 
Telephone:  415-978-1200 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
1.93 (3.80%)  
Trade Time: 
Jan 18  
Market Cap: 
Trade FGEN now with 

© 2019  
Description of Business
We are a science-based biopharmaceutical company discovering and developing first-in-class therapeutics. Roxadustat (FG-4592), our most advanced product candidate, is an oral small molecule inhibitor of HIF prolyl hydroxylase ("HIF-PH") activity in Phase 3 clinical development for the treatment of anemia in chronic kidney disease ("CKD"). Pamrevlumab (FG-3019), a fully-human monoclonal antibody that inhibits the activity of connective tissue growth factor ("CTGF"), is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis ("IPF"), pancreatic cancer, and Duchenne muscular dystrophy ("DMD"). We have taken a global approach to the development and future commercialization of our product candidates, which includes development and commercialization in the People's Republic of China ("China").
Register and access this filing in: